HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, G. Articles by DeMatteo, R. P. Search for Related Content PubMed PubMed Citation Articles by Miller, G. Articles by DeMatteo, R. P.

Murine Flt3 Ligand Expands Distinct Dendritic Cells with Both Tolerogenic and Immunogenic Properties ¹

Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021

Human Flt3 ligand can expand dendritic cells (DC) and enhance immunogenicity in mice. However, little is known about the effects of murine Flt3 ligand (mFlt3L) on mouse DC development and function. We constructed a vector to transiently overexpress mFlt3L in mice. After a single treatment, up to 44% of splenocytes became CD11c⁺ and the total number of DC increased 100-fold. DC expansion effects lasted for >35 days. mFlt3L DC were both phenotypically and functionally distinct. They had increased expression of MHC and costimulatory molecules and expressed elevated levels of B220 and DEC205 but had minimal CD4 staining. mFlt3L DC also had a markedly altered cytokine profile, including lowered secretion of IL-6, IL-10, IFN-, and TNF-, but had a slightly increased capacity to stimulate T cells in vitro. However, in a variety of in vivo models, DC expanded by mFlt3L induced tolerogenic effects on T cells. Adoptive transfer of Ag-pulsed mFlt3L splenic DC to naive mice actually caused faster rates of tumor growth and induced minimal CTL compared with control DC. mFlt3L also failed to protect against tumors in which human Flt3 ligand was protective, but depletion of CD4⁺ T cells restored tumor protection. Our findings 1) demonstrate that mFlt3L has distinct effects on DC development, 2) suggest an important role for mFlt3L in generating DC that have tolerogenic effects on T cells, and 3) may have application in immunotherapy in generating massive numbers of DC for an extended duration.

This article has been cited by other articles:

				T. L. Papenfuss, A. P. Kithcart, N. D. Powell, M. A. McClain, I. E. Gienapp, T. M. Shawler, and C. C. Whitacre Disease-modifying capability of murine Flt3-ligand DCs in experimental autoimmune encephalomyelitis J. Leukoc. Biol., December 1, 2007; 82(6): 1510 - 1518. [Abstract] [Full Text] [PDF]

				N. ONAI, A. OBATA-ONAI, M. A. SCHMID, and M. G. MANZ Flt3 in Regulation of Type I Interferon-Producing Cell and Dendritic Cell Development Ann. N.Y. Acad. Sci., June 1, 2007; 1106(1): 253 - 261. [Abstract] [Full Text] [PDF]

				U. I. Chaudhry, T. P. Kingham, G. Plitas, S. C. Katz, J. R. Raab, and R. P. DeMatteo Combined Stimulation with Interleukin-18 and CpG Induces Murine Natural Killer Dendritic Cells to Produce IFN-{gamma} and Inhibit Tumor Growth Cancer Res., November 1, 2006; 66(21): 10497 - 10504. [Abstract] [Full Text] [PDF]

				R. Chavan, K. A. Marfatia, I. C. An, D. A. Garber, and M. B. Feinberg Expression of CCL20 and Granulocyte-Macrophage Colony-Stimulating Factor, but Not Flt3-L, from Modified Vaccinia Virus Ankara Enhances Antiviral Cellular and Humoral Immune Responses. J. Virol., August 1, 2006; 80(15): 7676 - 7687. [Abstract] [Full Text] [PDF]

				U. I. Chaudhry, S. C. Katz, T. P. Kingham, V. G. Pillarisetty, J. R. Raab, A. B. Shah, and R. P. DeMatteo In vivo overexpression of Flt3 ligand expands and activates murine spleen natural killer dendritic cells FASEB J, May 1, 2006; 20(7): 982 - 984. [Abstract] [Full Text] [PDF]

				N. Onai, A. Obata-Onai, R. Tussiwand, A. Lanzavecchia, and M. G. Manz Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon-producing and dendritic cell development J. Exp. Med., January 23, 2006; 203(1): 227 - 238. [Abstract] [Full Text] [PDF]

				J. P. J. J. Hegmans, A. Hemmes, J. G. Aerts, H. C. Hoogsteden, and B. N. Lambrecht Immunotherapy of Murine Malignant Mesothelioma Using Tumor Lysate-pulsed Dendritic Cells Am. J. Respir. Crit. Care Med., May 15, 2005; 171(10): 1168 - 1177. [Abstract] [Full Text] [PDF]

				V. G. Pillarisetty, S. C. Katz, J. I. Bleier, A. B. Shah, and R. P. DeMatteo Natural Killer Dendritic Cells Have Both Antigen Presenting and Lytic Function and in Response to CpG Produce IFN-{gamma} via Autocrine IL-12 J. Immunol., March 1, 2005; 174(5): 2612 - 2618. [Abstract] [Full Text] [PDF]

				T. J. Fry, M. Sinha, M. Milliron, Y.-W. Chu, V. Kapoor, R. E. Gress, E. Thomas, and C. L. Mackall Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitution Blood, November 1, 2004; 104(9): 2794 - 2800. [Abstract] [Full Text] [PDF]

				J. A. Tobar, P. A. Gonzalez, and A. M. Kalergis Salmonella Escape from Antigen Presentation Can Be Overcome by Targeting Bacteria to Fc{gamma} Receptors on Dendritic Cells J. Immunol., September 15, 2004; 173(6): 4058 - 4065. [Abstract] [Full Text] [PDF]

				A. L. Mellor, B. Baban, P. Chandler, B. Marshall, K. Jhaver, A. Hansen, P. A. Koni, M. Iwashima, and D. H. Munn Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion J. Immunol., August 15, 2003; 171(4): 1652 - 1655. [Abstract] [Full Text] [PDF]